Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study

Jørgen Matz, Claus Graff, Petri J Vainio, Antero Kallio, Astrid Maria Højer, Johannes J. Struijk, Jørgen Kanters, Mads P Andersen, Egon Toft

    19 Citationer (Scopus)

    Abstract

    Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).
    OriginalsprogEngelsk
    TidsskriftClinical Drug Investigation
    Vol/bind31
    Udgave nummer11
    Sider (fra-til)799-811
    Antal sider13
    ISSN1173-2563
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study'. Sammen danner de et unikt fingeraftryk.

    Citationsformater